ADial Pharmaceuticals Announces Issuance Of First U.S. Patent

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHARLOTTESVILLE, Va., April 30, 2014 (GLOBE NEWSWIRE) -- ADial Pharmaceuticals, LLC (ADial), announced today the issuance of U.S. Patent No. 8,697,361 which covers the use of a serotonin-3 (5-HT3) antagonist for the treatment of alcohol related diseases, including Alcohol Use Disorder (AUD), in patients having the LL/TT genotype of the serotonin transporter gene. This patent will provide protection through at least April 28, 2030.

Help employers find you! Check out all the jobs and post your resume.

Back to news